Alameda, California, July 08, 2026. Vivani Medical, Inc. (Nasdaq: VANI), a biopharmaceutical company building long-acting drug implants, has entered into an agreement that allows Novo Nordisk to evaluate NPM-139, Vivani’s semaglutide implant now in development for chronic weight management. The implant is built on the company’s proprietary NanoPortal platform. The agreement carries no exclusivity, meaning neither NPM-139 nor the NanoPortal technology is tied up on Novo Nordisk’s behalf.
Terms of the Agreement
Novo Nordisk will run an internal, non-exclusive evaluation of the semaglutide implants that Vivani provides. Because the arrangement grants no exclusive rights, Vivani retains full freedom to pursue additional partnerships around both the implant and the platform behind it.
Adam Mendelsohn, Ph.D., president and chief executive of Vivani, said the agreement reflects Novo Nordisk’s interest in taking a closer look at the company’s technology and its work with semaglutide. He said the deal reinforces Vivani’s confidence in the commercial opportunity for GLP-1 implants and noted that candidates such as NPM-139 could serve a growing population of patients who would prefer to dose once or twice a year and who value knowing that treatment can be stopped whenever it needs to be.
Phase 1 Study Planned for Mid-2026
Separately, Vivani intends to begin Phase 1 studies in the middle of 2026. The trial will mark the first randomized human evaluation of the NPM-139 semaglutide implant, with Wegovy injection used as an active comparator. Its purpose is to characterize the implant’s safety, pharmacokinetics, and tolerability. Positive early findings would provide the foundation for a Phase 2 study aimed at establishing the appropriate dose range.
About Vivani Medical, Inc.
Vivani develops biopharmaceutical implants on its proprietary NanoPortal platform, engineered to release drug molecules at a steady rate over long stretches of time. The company’s central aim is to support treatment adherence while improving how well patients tolerate their medication. Vivani is assembling a portfolio of GLP-1 implants for metabolic conditions, including obesity and type 2 diabetes. These implants are designed to help patients capture the full benefit of their medicine while avoiding the difficulties that come with daily or weekly dosing, whether oral or injectable, including tolerability issues and diminishing effectiveness. Non-adherence, which occurs when patients do not take their medication as prescribed, affects a striking share of patients, roughly half, including those managing a once-daily pill.
Forward-Looking Statements
This press release contains forward-looking statements made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, identified by words such as “believe,” “expect,” “will,” “anticipate,” “estimate,” and “potential.” These statements rest on Vivani’s current beliefs and assumptions and are not guarantees of future performance. Because they concern the future, they carry risks and uncertainties largely outside the company’s control, and actual results could differ materially due to factors such as unexpected costs or delays and the broader risks of developing and commercializing product candidates. Additional detail appears in Vivani’s SEC filings, including its Quarterly Report on Form 10-Q filed on May 13, 2026. Each statement reflects only the information available as of today, and Vivani assumes no obligation to update it except as required by law.